Get the Stockscreener App
1.87
8.33%
-0.17
Quince Therapeutics Inc stock is traded at $1.87, with a volume of 441.70K.
It is down -8.33% in the last 24 hours and up +16.15% over the past month.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
See More
Previous Close:
$2.04
Open:
$2.1
24h Volume:
441.70K
Relative Volume:
1.70
Market Cap:
$100.44M
Revenue:
-
Net Income/Loss:
$-31.39M
P/E Ratio:
-2.2262
EPS:
-0.84
Net Cash Flow:
$-18.45M
1W Performance:
+13.33%
1M Performance:
+16.15%
6M Performance:
+85.15%
1Y Performance:
+159.72%
1-Day Range:
$1.85
$2.16
1-Week Range:
$1.62
$2.16
52-Week Range:
$0.69
$2.45
Quince Therapeutics Inc Stock (QNCX) Company Profile
Name
Quince Therapeutics Inc
Sector
Industry
Phone
415-910-5717
Address
611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO
Compare QNCX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QNCX
Quince Therapeutics Inc
|
1.87 | 109.58M | 0 | -31.39M | -18.45M | -0.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Quince Therapeutics Inc Stock (QNCX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-05-25 | Initiated | Citizens JMP | Mkt Outperform |
| Mar-24-25 | Initiated | Oppenheimer | Outperform |
Quince Therapeutics Inc Stock (QNCX) Latest News
Is Quince Therapeutics Inc. stock a good choice for value investorsWeekly Profit Recap & Safe Entry Trade Reports - newser.com
Quince Therapeutics Inc. stock daily chart insightsMarket Risk Report & Fast Moving Stock Watchlists - newser.com
Quince Therapeutics' (QNCX) Sell (D-) Rating Reaffirmed at Weiss Ratings - MarketBeat
Is Quince Therapeutics Inc. trending in predictive chart modelsJuly 2025 Analyst Calls & Free Fast Gain Swing Trade Alerts - newser.com
Quince Therapeutics Presents Data from Patient-Reported Walking Capacity in Children with Ataxia-Tel - PharmiWeb.com
Quince Therapeutics presents A-T walking capacity data at neurology meeting By Investing.com - Investing.com Canada
Quince Therapeutics (QNCX) Highlights Walking Study at Neurology Meeting - GuruFocus
Quince Therapeutics presents A-T walking capacity data at neurology meeting - Investing.com
Quince Therapeutics Presents Data from Patient-Reported Walking Capacity in Children with Ataxia-Telangiectasia at 54th Child Neurology Society Annual Meeting - Business Wire
Quince Therapeutics Inc. stock outlook for YEAREarnings Risk Summary & Free High Return Stock Watch Alerts - newser.com
Visual trend scoring systems applied to Quince Therapeutics Inc.Risk Management & Real-Time Volume Analysis Alerts - newser.com
Will Quince Therapeutics Inc. stock deliver shareholder value2025 Technical Overview & Reliable Breakout Forecasts - newser.com
Has Quince Therapeutics Inc. formed a bullish divergenceEarnings Overview Report & High Return Stock Watch Alerts - newser.com
Can Quince Therapeutics Inc. stock hit analyst price targetsJuly 2025 Breakouts & Expert Verified Stock Movement Alerts - newser.com
Analysts Set Quince Therapeutics, Inc. (NASDAQ:QNCX) PT at $8.14 - Defense World
Is Quince Therapeutics (NASDAQ:QNCX) Using Too Much Debt? - simplywall.st
What drives Quince Therapeutics Inc stock priceFinancial Sector Performance & Minimal Investment Capital - earlytimes.in
Will Quince Therapeutics Inc. bounce back from current supportWatch List & Reliable Price Breakout Alerts - newser.com
Applying Wyckoff theory to Quince Therapeutics Inc. stock2025 AllTime Highs & Daily Chart Pattern Signals - newser.com
Applying Elliott Wave Theory to Quince Therapeutics Inc.Recession Risk & Verified Momentum Watchlists - newser.com
Oppenheimer Sticks to Their Buy Rating for Quince Therapeutics (QNCX) - The Globe and Mail
Oppenheimer Maintains Quince Therapeutics(QNCX.US) With Buy Rating, Maintains Target Price $10 - 富途牛牛
Chart based analysis of Quince Therapeutics Inc. trendsJuly 2025 Volume & Real-Time Stock Price Movement Reports - newser.com
Quince Therapeutics stock maintains Market Outperform rating at Citizens - Investing.com
Aqua Metals files to sell 1M shares of common stock for holders - MSN
Transcript : Quince Therapeutics, Inc.Analyst/Investor Day - MarketScreener
Quince Therapeutics (NASDAQ:QNCX) Stock Price Up 1.2% – Time to Buy? - Defense World
Quince Therapeutics Inc Stock (QNCX) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):